Sanofi Hampered By Fitusiran Clinical Hold In Hemophilia

Reports Of Non-Fatal Thrombotic Events

The French major stressed to Scrip that patients enrolled in its fitusiran clinical trials often have other health issues and various co-morbidities, so it is too early to know if the adverse events are treatment-related.

RNA
Fitusiran is a subcutaneously administered RNAi therapeutic • Source: Shutterstock

Sanofi's hopes for fitusiran have suffered a setback with the news that all Phase III studies of the RNA interference-based hemophilia therapy have been put on hold over new adverse event concerns.

The French major has confirmed to Scrip that on 30 October, "we voluntarily paused dosing and enrolment in the ongoing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Blood and Clotting

More from Therapeutic Category